Tadalafil
FDA-approved product (tablet, oral), marketed as Adcirca, Alyq, Chewtadzy and 3 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Benign prostatic hyperplasia
- Erectile dysfunction
- Impotence
- Pulmonary arterial hypertension
- Pulmonary hypertension
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Drugs used in erectile dysfunction
- FDA pharmacologic class
- Phosphodiesterase 5 Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA50.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli30.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae23.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Tadalafil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm95.6% AI-predicted activityagainst MRSALab records exist50+ registered studies
- TaurursodiolExisting use: Bile acids and derivatives79.6% AI-predicted activityagainst MRSA43 registered studies
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome74.5% AI-predicted activityagainst MRSA50+ registered studies
- PlecanatideExisting use: Constipation74.4% AI-predicted activityagainst MRSA15 registered studies
- OxytocinExisting use: Hemorrhage, Uterine Inertia74.2% AI-predicted activityagainst MRSA50+ registered studies
- PosaconazoleExisting use: Aspergillosis, Candidiasis, Coccidioidomycosis and 2 more72.2% AI-predicted activityagainst MRSA50+ registered studies
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma70.6% AI-predicted activityagainst MRSA50+ registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more70.1% AI-predicted activityagainst MRSA50+ registered studies
- Quizartinib DihydrochlorideExisting use: Acute myeloid leukemia, Myeloid leukemia70.0% AI-predicted activityagainst MRSA4 registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more70.0% AI-predicted activityagainst MRSA50+ registered studies
- Deoxycholic AcidExisting use: Other dermatologicals69.3% AI-predicted activityagainst MRSA50+ registered studies
- ChenodiolExisting use: Cerebrotendinous xanthomatosis, Inborn errors of metabolism69.2% AI-predicted activityagainst MRSA30 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Study the Safety and Effectiveness of Tadalafil in Men With Diabetes Who Have Problems Getting and Keeping an Erection
NCT00547183 · start 2004-10
Registered record
- Registry ID
- NCT00547183
- Conditions
- Impotence
- Interventions
- tadalafil; tadalafil; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2004-10
- Completion
- 2005-05
- Enrolment
- 298
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionImpotenceInterventiontadalafil; tadalafil; placeboPhasePhase 3Registry statusCompletedA Study to Evaluate the Efficacy and Safety of 2.5mg and 5mg Tadalafil Given Once a Day to Men With Erectile Dysfunction
NCT00381732 · start 2003-10
Registered record
- Registry ID
- NCT00381732
- Conditions
- Erectile Dysfunction
- Interventions
- tadalafil; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-10
- Completion
- 2006-06
- Enrolment
- 280
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventiontadalafil; placeboPhasePhase 3Registry statusCompletedTo Determine Effect and Safety of Tadalafil Taken by Men of Different Races and With Different Diseases When Needed for Erections
NCT00547417 · start 2003-07
Registered record
- Registry ID
- NCT00547417
- Conditions
- Impotence
- Interventions
- tadalafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-07
- Completion
- 2004-03
- Enrolment
- 1,933
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionImpotenceInterventiontadalafilPhasePhase 3Registry statusCompletedDetermine Safety and Effectiveness of Tadalafil in Asian Men When Taken as Needed for Getting and Keeping an Erection
NCT00547573 · start 2003-04
Registered record
- Registry ID
- NCT00547573
- Conditions
- Impotence
- Interventions
- tadalafil; tadalafil; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-04
- Completion
- 2003-12
- Enrolment
- 367
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionImpotenceInterventiontadalafil; tadalafil; placeboPhasePhase 3Registry statusCompletedDetermine If the Stress That Comes With Not Developing an Erection Affects Tadalafil Effects
NCT00547599 · start 2003-04
Registered record
- Registry ID
- NCT00547599
- Conditions
- Impotence
- Interventions
- tadalafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2003-04
- Completion
- 2004-01
- Enrolment
- 659
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionImpotenceInterventiontadalafilPhasePhase 4Registry statusCompleted